Sentence examples for encouraging efficacy from inspiring English sources
Preclinical studies of capecitabine/taxane combination therapy demonstrated synergistic antitumour activity and phase I studies showed encouraging efficacy.
To overcome these side effects, the dose has been reduced to 1000 mg/m2 twice daily with a better therapeutic profile and encouraging efficacy.
The encouraging efficacy end points suggest that the further study of bevacizumab with chemoradiotherapy is warranted.
Bevacizumab targeting tumor angiogenesis showed encouraging efficacy as the first-line therapy for patients with advanced non-squamous NSCLC [7].
Applications in man showed, in general, reduced toxicity and better tolerability of administration with not too encouraging efficacy.
Continuous-infusion busulfan with intermittent fludarabine provides an alternative treatment strategy that is generally well tolerated and permits an increase in total busulfan dose with encouraging efficacy.
For future intended use in humans, we are now working on a new less immunogenic humanized version of the radioimmunoconjugate. Here, we demonstrate the encouraging therapeutic efficacy of 177Lu-m11B6, targeting the human kallikrein-related peptidase 2, with low observed adverse effects.
The encouraging clinical efficacy of immune checkpoint inhibitors has fueled an unprecedented level of research and development (R&D) activity and investment related to cancer immunotherapy.
This prospective study suggests that docetaxel in combination with irinotecan shows an encouraging antitumor efficacy with a manageable toxicity profile in children and young adults with recurrent and/or refractory ESFT, who have been heavily pre-treated.
The Btk inhibitor, ibrutinib (Imbruvica, Pharmacyclics), was approved by the US FDA in November 2013 for treating mantle cell lymphomas [ 19] and presented encouraging clinical efficacy and tolerability profiles in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomas [ 20].
Despite the encouraging clinical efficacy delivered by targeted agents, these monotherapies benefit only small subsets of patients with oncogene-driven tumors and, further, virtually all develop resistance and succumb to relapsed diseases [ 11].
